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2008-2009 Influenza Season 
Week 27 ending July 11, 2009 
All data are preliminary and may change as more reports are received. 
 
On June 11, the World Health Organization raised the pandemic alert level from Phase 5 to Phase 
6 indicating that an influenza pandemic is underway.   
 
Synopsis:  During week 27 (July 5-11, 2009), influenza activity decreased in the United States, 
however, there were still higher levels of influenza-like illness than is normal for this time of year.   
o One thousand two hundred seventy-eight (23.8%) specimens tested by U.S. World Health 
Organization (WHO) and National Respiratory and Enteric Virus Surveillance System (NREVSS) 
collaborating laboratories and reported to CDC/Influenza Division were positive for influenza. 
o Over 99% of all subtyped influenza A viruses being reported to CDC were novel influenza A 
(H1N1) viruses. 
o The proportion of deaths attributed to pneumonia and influenza (P&I) was below the epidemic 
threshold.  
o One influenza-associated pediatric death was reported and was associated with novel influenza 
A (H1N1) virus infection. 
o The proportion of outpatient visits for influenza-like illness (ILI) was below national and 
region-specific baseline levels. 
o Nine states reported geographically widespread influenza activity, 12 states and Puerto Rico 
reported regional influenza activity, 12 states and the District of Columbia reported local 
influenza activity, 16 states reported sporadic influenza activity, and one state did not report. 
 
National and Regional Summary of Select Surveillance Components 
 Data for current week Data cumulative for the season 
HHS 
Surveillance 
Regions* 
Out-
patient 
ILI† 
% 
positive 
for flu‡ 
Number of  
jurisdictions 
reporting 
regional or 
widespread 
activity§  
A (H1) A (H3) 
Novel A 
(H1N1) 
A  
(unable 
to sub-
type)¥ 
A 
(Subty-
ping 
not 
perfor-
med) 
B  Pediatric Deaths 
Nation Normal 23.8% 22 of 52 7,897 2,380 22,076 668 16,686 10,653 90 
Region I Normal 21.8% 4 of 6 540 157 1,800 13 1,669 815 4 
Region II Normal 25.9% 3 of 3 277 140 956 20 2,252 711 15 
Region III Normal 42.9% 4 of 6 1,249 219 3,567 13 921 1,361 9 
Region IV Normal 28.7% 3 of 8 831 131 1,010 49 2,511 1,221 6 
Region V Normal 34.4% 0 of 6 1,650 201 8,067 182 840 1,420 15 
Region VI Normal 23.3% 1 of 5 800 278 2,318 5 4,328 2,629 15 
Region VII Normal 26.0% 1 of 4 521 77 570 81 491 535 0 
Region VIII Normal 17.2% 0 of 6 530 217 1,132 61 1,594 499 7 
Region IX Normal 15.3% 4 of 4 1,111 647 908 35 1,589 771 17 
Region X Normal 24.5% 2 of 4 388 313 1,667 209 491 691 2 
* HHS regions (Region I: CT, ME, MA, NH, RI, VT; Region II: NJ, NY, Puerto Rico, US Virgin Islands; Region III: DE, DC, MD, PA, VA, WV; Region IV: AL, FL, GA, KY, MS, NC, 
SC, TN; Region V: IL, IN, MI, MN, OH, WI; Region VI: AR, LA, NM, OK, TX; Region VII: IA, KS, MO, NE; Region VIII: CO, MT, ND, SD, UT, WY; Region IX: AZ, CA, Guam, HI, 
NV; and Region X: AK, ID, OR, WA) 
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline 
‡ National data are for current week; regional data are for the most recent three weeks 
§ Includes all 50 states, the District of Columbia, and Puerto Rico 
¥ The majority of influenza A viruses that cannot be sub-typed as seasonal influenza viruses are novel A (H1N1) influenza viruses upon further testing 
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U.S. Virologic Surveillance:  WHO and NREVSS collaborating laboratories located in all 50 states 
and Washington D.C. report to CDC the number of respiratory specimens tested for influenza.  
 
During the 2008-09 season, influenza A (H1), A (H3), and B viruses have co-circulated in the United 
States.  On April 15 and 17, 2009, CDC confirmed the first two cases of novel influenza A (H1N1) 
virus in the United States. As of July 17, 2009, 40,617 confirmed and probable infections with novel 
influenza A (H1N1) virus and 211 deaths (7 deaths in individuals 0-4 years, 43 deaths in individuals 
5-24 years,101 deaths in adults 25-49 years, 66 deaths in adults 50-64 years, 23 deaths in adults 
age 65 and older and 22 deaths with unknown age) have been identified by CDC and state and 
local public health departments.  Reporting of novel influenza A (H1N1) viruses by U.S. WHO 
collaborating laboratories began during week 17 (week ending May 2, 2009).  The results of tests 
performed during the current week are summarized in the table below. 
 
 Week 27 
No. of specimens tested 5,371 
No. of positive specimens (%) 1,278 (23.8%) 
Positive specimens by type/subtype  
Influenza A              1,274 (99.7%) 
          A (novel H1N1)   808 (63.4%)  
          A (subtyping not performed)          457 (35.9%)
          A (unable to subtype)  6 (0.5%)  
          A (H3)                3 (0.2%) 
          A (H1) 0 (0.0%)
Influenza B                   4 (0.3%) 
 
During week 27, seasonal influenza A (H1), A (H3), and B viruses co-circulated at low levels with 
novel influenza A (H1N1) viruses.  Over 99% of all subtyped influenza A viruses being reported to 
CDC this week were novel influenza A (H1N1) viruses. 
 
The increase in the percentage of specimens testing positive for influenza by WHO and NREVSS 
collaborating laboratories may be due in part to changes in testing practices by health care 
providers, triaging of specimens by public health laboratories, an increase in the number of 
specimens collected from outbreaks, and other factors. 
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Influenza Positive Tests Reported to CDC by U.S. WHO/NREVSS 
Collaborating Laboratories, National Summary, 2008-09 
0
500
1000
1500
2000
2500
3000
3500
4000
4500
40 42 44 46 48 50 52 1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35
Week
N
um
be
r o
f P
os
iti
ve
 S
pe
ci
m
en
s
0
5
10
15
20
25
30
35
40
45
50
55
P
er
ce
nt
 P
os
iti
ve
 
A (Novel H1N1)
A (Unable to Subtype)
A (H3)
A (H1)
A (Subtyping not Performed)
B
Percent Positive
 
Antigenic Characterization:  CDC has antigenically characterized 1,817 seasonal human 
influenza viruses [1,049 influenza A (H1), 196 influenza A (H3) and 572 influenza B viruses] 
collected by U.S. laboratories since October 1, 2008, and 233 novel influenza A (H1N1) viruses. 
All 1,049 influenza seasonal A (H1) viruses are related to the influenza A (H1N1) component of the 
2008-09 influenza vaccine (A/Brisbane/59/2007).  One hundred eighty-eight (96%) of 196 influenza 
A (H3N2) viruses tested are related to the A (H3N2) vaccine component (A/Brisbane/10/2007) and 
eight viruses (4%) tested showed reduced titers with antisera produced against 
A/Brisbane/10/2007.  
All 233 novel influenza A (H1N1) viruses are related to the A/California/07/2009 (H1N1) reference 
virus selected by WHO as a potential candidate for novel influenza A (H1N1) vaccine. 
Influenza B viruses currently circulating can be divided into two distinct lineages represented by the 
B/Yamagata/16/88 and B/Victoria/02/87 viruses. Sixty-eight (12%) of 573 influenza B viruses tested 
belong to the B/Yamagata lineage and are related to the vaccine strain (B/Florida/04/2006). The 
remaining 504 (88%) viruses belong to the B/Victoria lineage and are not related to the vaccine 
strain.  
Data on antigenic characterization should be interpreted with caution given that antigenic 
characterization data is based on hemagglutination inhibition (HI) testing using a panel of reference 
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ferret antisera and results may not correlate with clinical protection against circulating viruses 
provided by influenza vaccination. 
Annual influenza vaccination is expected to provide the best protection against those virus 
strains that are related to the vaccine strains, but limited to no protection may be expected when the 
vaccine and circulating virus strains are so different as to be from different lineages, as is seen with 
the two lineages of influenza B viruses.  Antigenic characterization of novel influenza A (H1N1) 
viruses indicates that these viruses are antigenically and genetically unrelated to seasonal influenza 
A (H1N1) viruses, suggesting that little to no protection would be expected from vaccination with 
seasonal influenza vaccine.  
Antiviral Resistance: Since October 1, 2008, 1,071 seasonal influenza A (H1N1), 201 influenza A 
(H3N2), and 606 influenza B viruses have been tested for resistance to the neuraminidase 
inhibitors (oseltamivir and zanamivir).  Also, 1,078 seasonal influenza A (H1N1) and 212 influenza 
A (H3N2) viruses have been tested for resistance to the adamantanes (amantadine and 
rimantadine).  Two hundred sixty-seven novel influenza A (H1N1) viruses have been tested for 
resistance to the neuraminidase inhibitors (oseltamivir and zanamivir).  Three hundred five novel 
influenza A (H1N1) viruses have been tested for resistance to the adamantanes (amantadine and 
rimantadine).  The results of antiviral resistance testing performed on these viruses are summarized 
in the table below. 
 
Resistant Viruses, 
Number (%) 
Resistant 
Viruses, Number 
(%)  Isolates tested (n) 
Oseltamivir Zanamivir 
Isolates 
tested (n) 
Adamantanes 
Seasonal Influenza 
A (H1N1) 1,071 1,066 (99.5%) 0 (0) 1,078 6 (0.6%) 
Influenza A (H3N2) 201 0 (0) 0 (0) 212 212 (100%) 
Influenza B 606 0 (0) 0 (0) N/A* N/A* 
Novel Influenza A  
(H1N1) 267 0 (0) 0 (0) 305 305 (100%) 
*The adamantanes (amantadine and rimantadine) are not effective against influenza B viruses. 
 
The novel influenza A (H1N1) virus is susceptible to both neuraminidase inhibitor antiviral 
medications zanamivir and oseltamivir.  It is resistant to the adamantane antiviral medications, 
amantadine and rimantadine. Antiviral treatment with either oseltamivir or zanamivir is 
recommended for all patients with confirmed, probable or suspected cases of novel influenza A 
(H1N1) virus infection who are hospitalized or who are at higher risk for seasonal influenza 
complications.   
 
Three cases of oseltamivir resistant novel influenza A (H1N1) viruses have been detected 
worldwide, none of which were detected in the U.S.  However, one of the three viruses was 
detected in a specimen collected from a child that became ill in California and subsequently 
traveled to Hong Kong where the respiratory specimen was collected, and the oseltamivir resistant 
novel H1N1 strain was detected.  Enhanced antiviral resistance testing in California has not 
revealed any other oseltamivir resistant novel influenza A (H1N1) viruses.  The other two cases of 
oseltamivir resistant novel H1N1 viruses were detected in Japan and Denmark.   
(http://www.who.int/csr/disease/swineflu/newsbriefs/h1n1_antiviral_resistance_20090708/en/index.
html). Additional information on antiviral recommendations for treatment and chemoprophylaxis of 
novel influenza A (H1N1) infection is available at http://www.cdc.gov/h1n1flu/recommendations.htm. 
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Three seasonal influenza A (H1N1) viruses collected between February 8 and May 11, 2009 were 
found to be resistant to both oseltamivir and the adamantanes (amantadine and rimantadine).  All 
influenza A (H1N1) viruses tested retain their sensitivity to zanamivir.  The three dually resistant 
viruses represent less than 0.5% of all seasonal influenza A (H1N1) viruses tested during the 2008-
09 influenza season, and as a result, no changes to the influenza antiviral treatment or prophylaxis 
recommendations will be made at this time.  CDC will continue to monitor trends in antiviral 
resistance over the summer and throughout the upcoming 2009-10 influenza season.   
 
 
Pneumonia and Influenza (P&I) Mortality Surveillance:  During week 27, 6.5% of all deaths 
reported through the 122-Cities Mortality Reporting System were due to P&I. This percentage was 
below the epidemic threshold of 6.6% for week 27. 
 
 
Pneumonia and Influenza Mortality for 122 U.S. Cities 
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Influenza-Associated Pediatric Mortality:  One influenza-associated pediatric death was reported 
to CDC during week 27 (Massachusetts).  This death was associated with a novel influenza A 
(H1N1) virus infection.  The death reported this week occurred during week 27 (the week ending 
July 11, 2009).  Since September 28, 2008, CDC has received 90 reports of influenza-associated 
pediatric deaths that occurred during the current influenza season, 23 of which were due to novel 
influenza A (H1N1) virus infections.   
 
Of the 40 children who had specimens collected for bacterial culture from normally sterile sites, 15 
(37.5%) were positive; Staphylococcus aureus was identified in nine (60.0%) of the 15 children.    
Four of the S. aureus isolates were sensitive to methicillin and five were methicillin resistant.   
Thirteen (86.7%) of the 15 children with bacterial coinfections were five years of age or older and 10 
(66.7%) of the 15 children were 12 years of age or older.  Nine of the 23 children with confirmed 
novel influenza A (H1N1) infection had a specimen collected from a normally sterile site; one of the 
nine children had a positive bacterial culture.  An increase in the number of influenza-associated 
pediatric deaths with bacterial coinfections was first recognized during the 2006-07 influenza 
season.  In January 2008, interim testing and reporting recommendations were released regarding 
influenza and bacterial coinfections in children and are available at 
(http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00268). 
 
Number of Influenza-Associated Pediatric Deaths by Week of Death: 
2005-06 season to present 
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Influenza-Associated Hospitalizations:  Laboratory-confirmed influenza-associated 
hospitalizations are monitored in two population-based surveillance networks: the New Vaccine 
Surveillance Network (NVSN) and the Emerging Infections Program (EIP).   
 
During October 12, 2008 to June 27, 2009, the preliminary laboratory-confirmed influenza-
associated hospitalization rate for children 0-4 years old in the NVSN was 4.42 per 10,000. 
Because of case identification methods utilized in this study, there is a delay from the date of 
hospitalization to the date of report.  
 
 
NVSN Influenza Laboratory-Confirmed Cumulative Hospitalization 
Rates for Children 0 - 4 Years, 2008-09 and Previous Three Seasons 
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During April 15, 2009 to July 11, 2009, the following preliminary laboratory-confirmed overall 
influenza associated hospitalization rates were reported by the EIP (rates include type A, type B, 
and novel H1N1): 
 
Rates for children aged 0-23 months, 2-4 years, and 5-17 years were 1.7, 0.7, and 0.6 per 10,000, 
respectively.  Rates for adults aged 18-49 years, 50-64 years, and ≥ 65 years were 0.3, 0.3, and 0.3 
per 10,000, respectively. 
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EIP Influenza Laboratory-Confirmed Cumulative Hospitalization Rates, 
Spring/Summer 2009 
*This value represents an age group-specific average influenza rate from October 1 to 
April 30 from the 2005-06, 2006-07, and 2007-08 influenza seasons.
**Note: The scales for the 0-23 month and the ≥65 year age groups differ from other age 
groups. 
**
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Outpatient Illness Surveillance: Nationwide during week 27, 1.3% of patient visits reported 
through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to 
influenza-like illness (ILI).  This percentage is below the national baseline of 2.4%. 
 
Percentage of Visits for Influenza-like Illness (ILI) Reported by  
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
National Summary, 2008-09 and Previous Two Seasons 
*There was no week 53 during the 2006-07 and 2007-08 seasons, therefore the week 53 data point for those seasons is an average of weeks 52 and 1.
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On a regional level, the percentage of outpatient visits for ILI ranged from 0.3% to 2.2%. All 10 
regions reported percentages of visits for ILI below their respective region-specific baselines.  ILI 
decreased during week 27 in six of 10 regions compared to week 26.   
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists:  The 
influenza activity reported by state and territorial epidemiologists indicates geographic spread of 
both seasonal influenza and novel influenza A (H1N1) viruses and does not measure the severity of 
influenza activity. 
 
During week 27, the following influenza activity was reported: 
? Widespread influenza activity was reported by nine states (California, Delaware, Georgia, 
Hawaii, Maine, Maryland, Nebraska, New Jersey, and New York). 
? Regional influenza activity was reported by Puerto Rico and 12 states (Arizona, Arkansas, 
Connecticut, Florida, Massachusetts, Nevada, North Carolina, Oregon, Pennsylvania, 
Rhode Island, Virginia, and Washington). 
? Local influenza activity was reported by the District of Columbia and 12 states (Alaska, 
Illinois, Michigan, Minnesota, New Hampshire, New Mexico, South Carolina, Tennessee, 
Texas, Utah, West Virginia, and Wisconsin). 
? Sporadic activity was reported by 16 states (Alabama, Colorado, Idaho, Indiana, Iowa, 
Kansas, Kentucky, Louisiana, Mississippi, Missouri, North Dakota, Ohio, Oklahoma, South 
Dakota, Vermont, and Wyoming). 
? One state did not report (Montana). 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm 
 
Report prepared: July 17, 2009. 
 
